There are questions about vuso-vec’s supporting and confirmatory trials.
ApexOnco Front Page
Recent articles
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
NVL-330 features among the latest crop of industry projects newly into human trials.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.